|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | European initiatives for better training in medicines development显示文摘In the last decade, the environment for medicines development has undergone unprecedented change, including: a shift from predominantly big Pharma to one of extensive industry-cademia and SME partnerships and collaborations, greater emphasis on understanding the molecular basis of disease for stratified and personalised medicine, and a focus on societal/patients?needs and priorities. A variety of European initiatives have been established to support the training of scientists/professionals involved in medicines development in order to respond to this constantly changing, demanding, and chaotic landscape. Some of these initiatives are directed specifically at medicines development, some address scientific research including training relevant to medicines development, and some support general training needs which can include medicines development. There are a number of European initiatives supporting better training in medicines development. They differ in their approach, ranging from IMI (specific to medicines development) to Erasmus+(boosting skills and employability in all areas). The scope, budgets, and requirements differ considerably and they each have to be reviewed in detail to decide which might be the most appropriate for a particular target group. The common theme is to support the aims of the European Research Area (ERA), i.e., a significant improvement in Europe's research performance to promote growth and job creation. | Mike Hardman | 2015 | Journal of Medicines Development Sciences2015，1，1： | 0 |
| 2 | Competencies: A new currency for continuing professional development显示文摘'No research without trained researchers' has become the mantra of the EU-funded Innovative Medicines Initiative (IMI) education and training projects. However, it is often hard to determine the type of training required at different stages of a scientist's career. The situation is further complicated by the constantly changing environment, e.g. the growth of disruptive technologies, societal expectations of biomedical sciences, the greater need for multi-disciplinary collaborations, and conservative or changing regulatory requirements. This article summarises the experience from a series of five EMTRAIN Public Private Partnership PhD workshops that included both scientific and transferrable skill training. This is followed by an example of a recently developed training programme, including a competency profile, for translational research and medicines development;the C-COMEND teaching programme. The emphasis is on competencies as a new currency for continuing professional development. Finally, this paper describes what we consider to be the next steps required by the scientific community to address solutions to the current training challenges so that society can benefit from the innovations that only science can provide. | Anita Aperia Jorgen Dirach Mike Hardman Christa Janko Jeff Kipling Rosan 0KreeftmeijerVegter Rebecca Ludwig Lena Scott Armel Stockis | 2016 | Journal of Medicines Development Sciences2016，2，2： | 0 |
| 3 | Competencies: A New Currency for Continuing Professional Development显示文摘“No research without trained researchers” has become the mantra of the EU-funded Innovative Medicines Initiative (IMI) education and training projects.However,it is often hard to know what training is required at different stages of scientists’ careers.The situation is further complicated by the constantly changing environment e.g.the growth of disruptive technologies,societal expectations of biomedical science,the greater need for multidisciplinary working,and conservative or changing regulatory requirements.This article summarises the experience from a series of five EMTRAIN Public Private Partnership PhD workshops that included both scientific and transferrable skill training.This is followed by an example of a recently developed training programme,including a competency profile,for translational research and medicines development;the C-COMEND teaching programme.Finally,this paper describes what we consider to be the next steps required by the scientific community to address solutions to the current training challenges so that society can benefit from the innovations that only science can provide. | Anita Aperia Jorgen Dirach Mike Hardman Christa Janko Jeff Kipling Rosan Kreeftmeijer-Vegter Rebecca Ludwig Lena Scott Armel Stockis | 2018 | Journal of Medicines Development Sciences2018，3，1： | 0 |
| 4 | It pays to promote joint PhD programmes between academia and the private sector显示文摘The prosperity of a country is closely related to its level of education to fuel research and innovation.Doctoral graduates have attained the highest education level and should be the key players in research and innovation.The number of doctoral graduates is increasing rapidly in most/many countries,but is less well correlated to changes in prosperity of a country.The innovative medicines initiative(IMI)was established to help Europe strengthen its position in biomedical research and development.During its planning stage IMI observed large gaps in the scientific interaction between academia and industry in Europe,and that undergraduate students were not realizing the career opportunities within biomedical R&D.A major objective for the education and training section of IMI,the European Medicines Research Training Network(EMTRAIN,http://www.emtrain.eu),has therefore been to work out a framework for public private partnership PhD(PPP-PhD)and to create a cohort of networking,industry-aware scientists. | Anita Aperia Jorgen Dirach Mike Hardman Christa Janko Jeff Kipling Rebecca Ludwig Lena Scott Armel Stockis | 2015 | Journal of Medicines Development Sciences2015，1，2： | 0 |
| 5 | LifeTrain:Driving lifelong learning for biomedical professionals显示文摘This article describes LifeTrain—the European common framework for continuing professional development in the biomedical sciences.An important goal of LifeTrain is to support biomedical professionals to work collaboratively across disciplines,sectors and national boundaries.LifeTrain is an open community with a unifying goal;it brings together many excellent,but disparate,activities into a process towards establishing a focused and coherent framework for continuing professional development in the biomedical sciences.This collaborative approach provides the critical mass to make a major contribution to strengthen the skills and competencies of biomedical professionals in a rapidly changing environment.LifeTrain's signatories,which include multinational pharmaceutical companies,research infrastructures,professional and scientific bodies,higher-education institutes and research institutes,have agreed to the principles of the framework and to continue to collaborate to implement LifeTrain.We warmly invite others to join us. | Cath Brooksbank Christa Janko Claire Johnson Wolf See Hans H. Lindén Mike Hardman | 2015 | Journal of Medicines Development Sciences2015，1，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员